tumor radioimmunoassay (RII)

Radioimmunoimaging (RII) is a kind of radioactive radionuclide that is used to cross-link diagnostic radionuclides to target tumor tissues, and uses nuclear medicine imaging equipment to detect tumor sites in vitro. Nuclear medicine diagnostic technology. A radionuclide-labeled specific antibody against a tumor antigen is introduced into the body via a certain route, which will bind to the antigen on the surface of the tumor cell, and a tumor-positive imaging which increases the radioactive aggregation in the tumor tissue. Basic Information Specialist Category: Oncology Inspection Category: Radionuclide Applicable gender: whether men and women apply fasting: fasting Analysis results: Below normal: Normal value: no Above normal: negative: normal. Positive: A tumor-positive imaging with increased radioactivity accumulation in tumor tissue yields a clear tumor image. Tumor RII can be characterized and localized to show primary and systemic metastases, especially for occult lesions that are difficult to identify with other diagnostic techniques. Tips: Please check the expedition to the undergraduate room on the same day. Some patients may require a laxative to clear the intestines before the imaging test. Normal value A tumor-positive imaging with increased radioactivity accumulation in tumor tissue yields a clear tumor image. Clinical significance Abnormal results: Tumor RII can be qualitatively and localized to show primary and systemic metastases, especially for occult lesions that are difficult to identify with other diagnostic techniques. Clinical data show that RII with different radionuclide-labeled monoclonal antibodies against different antigenic determinants of tumors has a sensitivity of 70% and a specificity of 90% for extrahepatic lesions of colorectal cancer, but for intrahepatic metastases. Sensitivity is inferior to CT; sensitivity to ovarian cancer is 60% to 80%; sensitivity to diagnosis of small cell and non-small cell lung cancer is 77% and 88%, respectively; sensitivity and specificity for detection of bladder cancer by intraperitoneal RII imaging The sex reached 90% and 80% respectively. People who need to be examined: General tumor patients need to be examined. Positive results may be diseases: ovarian yolk sac tumor, chest wall bone tumor, primary cutaneous B-cell lymphoma, epithelioid sarcoma, nerve sheath myxoma, Bowen's disease, pediatric posterior fossa ependymoma considerations Forbidden before inspection: Please check the expedition to the undergraduate room on the same day. Some patients may require a laxative to clear the intestines before the imaging test. Requirements for examination: 10 minutes before the start of the tracer injection and after the injection, the patient should be at rest and use a sedative if necessary. Blood glucose should be monitored before the tracer is injected. Inspection process The use of anti-tumor antibodies or fragments thereof as a specific targeting vehicle cross-linking diagnostic radionuclide localization to tumor tissue, using nuclear medicine imaging equipment to detect tumor location in vitro a nuclear medicine diagnostic technique. A radionuclide-labeled specific antibody against a tumor antigen is introduced into the body via a certain route, which will bind to the antigen on the surface of the tumor cell, and a tumor-positive imaging which increases the radioactive aggregation in the tumor tissue. Not suitable for the crowd Inappropriate crowd: None. Adverse reactions and risks Nothing.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.